MagForce AG engages in the development and distribution of a nanotechnology based cancer therapy. It offers Nanotherm therapy, which includes a liquid containing iron oxide nanoparticles that interact with an alternating magnetic field to destroy cancer cells, as well as an application, in which the progress of the therapy can be planned and documented. The company was founded in 1997 and is headquartered in Berlin, Germany.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company